Blueprint Genetics, a Helsinki, Finland-based developer of a clinical grade genetic diagnostics platform , raised $3.9m in funding.
Backers included Inventure and Avohoidon Tutkimussäätiö, a Finnish foundation, which joined existing Finnish business angels and Tekes, the Finnish Funding Agency for Innovation.
The company intends to use the funds to accelerate international expansion.
Led by Tommi Lehtonen, CEO, Blueprint Genetics provides a clinical grade genetic diagnostics platform which leverages a proprietary Next-Generation Sequencing (NGS) technology developed at Stanford University.
In 2013, the company entered the market with its first product category, providing diagnostics for inherited cardiovascular disorders.
Today, Blueprint Genetics serves more than 60 hospital customers in 10 countries, is continue to expand launching its US office to boost sales in North America.